Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Has Consensus Price Target of $377.20

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $377.20.

A number of equities research analysts have recently weighed in on KRYS shares. The Goldman Sachs Group initiated coverage on Krystal Biotech in a research report on Thursday, September 24th. They issued a “buy” rating and a $441.00 price objective on the stock. Bank of America upped their target price on Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a report on Monday, September 21st. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada started coverage on Krystal Biotech in a research note on Friday, August 14th. They issued an “outperform” rating and a $400.00 price target for the company. Finally, Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 9th.

Insiders Place Their Bets

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Krystal Biotech in the second quarter worth about $1,554,113,000. William Blair Investment Management LLC bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $211,909,000. Jupiter Topco LLC bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $95,387,000. Bank of America Corp DE bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $95,308,000. Finally, Bank of New York Mellon Corp bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $60,809,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $316.58 on Tuesday. The stock has a market capitalization of $9.37 billion, a PE ratio of 39.67 and a beta of 0.50. Krystal Biotech has a 1 year low of $183.03 and a 1 year high of $382.54. The business’s 50-day moving average is $340.41 and its 200 day moving average is $323.15.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The business had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. As a group, equities research analysts anticipate that Krystal Biotech will post 7.40 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.